Medical technology company Carl Zeiss Meditec successfully continued on its growth course in the third quarter and achieved a significant increase in revenue compared with the same period of the previ…
Medical technology company Carl Zeiss Meditec successfully continued on its growth course in the third quarter and achieved a significant increase in revenue compared with the same period of the previous year. I am particular pleased that this substantial growth in revenue has also had a positive effect on earnings, says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. The EBIT margin increased from 12.2% in the same period of the previous year to 13.6%. This takes us another step closer to achieving our objective of increasing our margin to 15% by around 2015, continues Dr. Monz. Carl Zeiss Meditec has a broad business portfolio, ranging from ophthalmology, through microsurgery, to new applications in radiotherapy. All strategic business units and reporting regions are contributing to our growth. This shows that our company is in a stable position, says Dr. Ludwin Monz. In the first nine months of the current financial year Carl Zeiss Meditec generated consolidated revenue of EUR 555.5 million (previous year: EUR 490.8 million). This represents an increase of 13.2% over the previous year. Growth came from all strategic business units (SBUs). Both the overall positive trend in the market during the reporting period and the further improvement in the company“s position as a result of innovative new products contributed to this development. The Microsurgery SBU grew by 20.8% compared with the previous year. The significantly higher sales of the innovative radiotherapy device INTRABEAM contributed to this. While the Ophthalmic Systems SBU grew by 8.3%, the Surgical Ophthalmology SBU contributed to overall earnings with growth of 7.7%. Revenue growth comes from all reporting regions of Carl Zeiss Meditec. The Asia/Pacific region achieved the greatest growth in revenue of EUR 174.2 million (23.9%). As in the previous quarters, China, India and Southeast Asia showed the most significant growth. The Americas region also achieved double-digit growth of 11.6%, to EUR 188.5 million. This region continues to be dominated by the US, although development in Central and South America is also encouraging. The EMEA region is the strongest market in terms of revenue generation, growing by 6.3% through the sale of products and solutions to a value of EUR 192.8 million. Earnings before interest and taxes (EBIT) increased to EUR 75.7 million (previous year: EUR 60 million). The EBIT margin increased from 12.2% to 13.6%. We shall remain on our present course, says Dr. Ludwin Monz. Our stable strategic presence in businesses and regions makes me optimistic about the longer-term development of our company. Particularly in light of the current imponderables concerning the global economy, I consider Carl Zeiss Meditec to be well equipped, said Dr. Monz.
